Table 2 Surgery and neoadjuvant chemotherapy
Characteristic | ER-Positive | ER-Negative | ||||
|---|---|---|---|---|---|---|
Age<35 | 35≤Age<50 | P-value | Age<35 | 35≤Age<50 | P-value | |
(N = 147) | (N = 901) | (N = 134) | (N = 663) | |||
Breast surgery | Â | Â | 0.626 | Â | Â | 0.125 |
 Conserving | 66 (44.9) | 424 (47.1) |  | 74 (55.2) | 318 (48.0) |  |
 Mastectomy | 81 (55.1) | 477 (52.9) |  | 60 (44.8) | 345 (52.0) |  |
Axillary surgery | Â | Â | 0.561 | Â | Â | 0.005 |
 SLNB | 19 (16.4) | 90 (10.0) |  | 27 (20.1) | 69 (10.4) |  |
 SLNB➔ALND | 43 (26.0) | 269 (29.9) |  | 27 (20.1) | 174 (26.2) |  |
 ALND | 85 (56.2) | 540 (59.9) |  | 80 (59.7) | 420 (63.3) |  |
 Unknown | 0 (0.0) | 2 (0.3) |  | 0 (0.0) | 0 (0.0) |  |
Neoadjuvant chemotherapy | Â | Â | 0.090 | Â | Â | 0.068 |
 Anthracycline-based | 111 (75.5) | 689 (76.5) |  | 107 (79.9) | 504 (74.7) |  |
 Trastuzumab-containg | 13 (8.8) | 515 (5.7) | 0.138 | 5 (3.7) | 58 (8.7) | 0.053 |
 Others | 8 (5.4) | 94 (10.4) |  | 9 (6.7) | 82 (12.1) |  |
 Unknown | 28 (19.0) | 118 (13.1) |  | 18 (13.4) | 89 (13.2) |  |